Efficacy and tolerability of methotrexate therapy for refractory intestinal Behçet's disease: a single center experience
Jihye Park, Jae Hee Cheon, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim
Intest Res. 2018;16(2):315-318.   Published online 2018 Apr 30     DOI: https://doi.org/10.5217/ir.2018.16.2.315
Citations to this article as recorded by Crossref logo
Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
Jae Hee Cheon
Journal of Rheumatic Diseases.2021; 28(1): 4.     CrossRef
Long-term outcome and predictors of remission in Behçet’s disease in daily practice
Aida Malek Mahdavi, Alireza Khabbazi, Mehrzad Hajialilo
Modern Rheumatology.2021; 31(6): 1148.     CrossRef
Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice
Da Hye Kim, Soochan Kim, Jae Bum Ahn, Jae Hyeon Kim, Hyun Woo Ma, Dong Hyuk Seo, Xiumei Che, Ki Cheong Park, Jeong Yong Jeon, Sang Yong Kim, Han Cheol Lee, Jae-Young Lee, Tae Il Kim, Won Ho Kim, Seung Won Kim, Jae Hee Cheon
International Journal of Medical Microbiology.2020; 310(2): 151391.     CrossRef
Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet’s disease
H. J. Kim, K.‑t. Kim, S.-G. Lee, Y. Kim
Zeitschrift für Rheumatologie.2020; 79(7): 702.     CrossRef
Safety of systemic treatments for Behçet’s syndrome
Giuseppe Lopalco, Donato Rigante, Antonio Lopalco, Giacomo Emmi, Vincenzo Venerito, Antonio Vitale, Giovanna Capozio, Nunzio Denora, Luca Cantarini, Florenzo Iannone
Expert Opinion on Drug Safety.2020; 19(10): 1269.     CrossRef
Update on the treatment of Behçet’s syndrome
Sinem Nihal Esatoglu, Gulen Hatemi
Internal and Emergency Medicine.2019; 14(5): 661.     CrossRef